Last reviewed · How we verify

NCT06223828: CR-AZI Kids

Azithromycin for Critical Asthma - Pediatrics

Recruiting now Phase 2, PHASE3 Last updated 17 December 2025
What this trial tests

Phase 2, PHASE3 trial testing Azithromycin in Pediatric Asthma in 100 participants. Currently enrolling.

Timeline
2 April 2024
Primary endpoint
31 July 2026
31 December 2026

Quick facts

Lead sponsorJohns Hopkins All Children's Hospital
PhasePhase 2, PHASE3
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment100
Start date2 April 2024
Primary completion31 July 2026
Estimated completion31 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins All Children's Hospital

Who can join

Adults 3 to 17, any sex, with Pediatric Asthma or Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Azithromycin

Trials testing the same drug.

Other recruiting trials for Pediatric Asthma

Currently open trials in the same condition.

Other Johns Hopkins All Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06223828.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing